Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin- dependent pathway while preventing graft-versus-host disease

Blood

Volumn 93, Issue 12, 1999, Pages 4071-4078

  Pan, Luying ^b   Teshima, Takanori ^b   Hill, Geoffrey R ^b   Bungard, David ^b   Brinson, Yani S ^b   Reddy, Vijay S ^b   Cooke, Kenneth R ^b   Ferrara, James L M ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033564653     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4071     Document Type: Article

References (73)

1. Truitt RL, Johnson BD, McCabe C, Weiler MB: Graft versus leukemia, in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft Versus Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Marcel Dekker, 1997, p 385
2. Weiden PL, Horowitz MM: Graft-vs-leukemia effect in clinical bone marrow transplantation, in Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K (eds): Graft-versus-Host Disease. New York, NY, Marcel Dekker, 1990, p 691
3. Barrett J, Malkovska V: The graft-versus-leukemia effect. Curr Opin Oncol 8:89, 1996
4. Champlin R, Giralt S, Gajewski J: T cells, graft-versus-host disease and graft-versus-leukemia: Innovative approaches for blood and marrow transplantation. Acta Haematol 95:157, 1996
5. Apperley JF, Jones L, Hale G, Goldman JM: Bone marrow transplantation for chronic myeloid leukemia: T cell depletion with Campath-1 reduces the incidence of acute graft-versus-host disease but may increase the risk of leukemia relapse. Bone Marrow Transplant 1:53, 1986
6. Prentice HG, Blacklock HA, Janossy G, Gilmore MJ, Price-Jones L, Tidman N, Trejdosiewicz LK, Skeggs DB, Panjwani D, Ball S: Depletion of T-lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukemic marrow transplant recipients. Lancet 1:472, 1984
7. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-verus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
8. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, Lilleby K, Rowley S, Sanders J, Storb R, Buckner CD: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 88:2794, 1996
9. Gratwohl A, Hermans J, Baldomero H: Blood and marrow transplantation activity in Europe 1995. Bone Marrow Transplant 19:407, 1997
10. Harada M, Shinagawa K, Kawano T, Kasai M, Sawada H, Nakao S, Hyodo H, Aotsuka N, Furukawa T, Hirai H, Eto T, Imai Y, Shimazaki C, Matsue K, Ogawa M, Takaku F: Allogeneic peripheral blood stem cell transplantation for standard-risk leukemia. A multicenter pilot study: Japanese experience. Japan Blood Cell Transplantation Study Group. Bone Marrow Transplant 21:S54, 1998 (suppl 3)
11. Cornelissen JJ, Fibbe WE, Schattenberg AV, Petersen EJ, Willemze R, de Witte TJ, Lowenberg B, Verdonck LF, vd Biezen A, Brand R: A retrospective Dutch study comparing T cell-depleted allogeneic blood stem cell transplantation vs T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 21:S66, 1998 (suppl 3)
12. Hartung T, Docke WD, Grabtner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482, 1995
13. Pan L, Delmonte J, Jalonen CK, Ferrara JLM: Pretreatment of donors with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type 2 cytokine production and reduces severity of experimental graft versus host disease. Blood 86:4422, 1995
14. Pan L, Bressler S, Cooke KR, Krenger W, Karandikar M, Ferrara JLM: Long-term engraftment, graft-versus-host disease, and immunologic reconstitution following experimental transplantation of allogeneic peripheral blood cells from G-CSF treated donors. Biol Blood Marrow Transplant 2:126, 1996
15. Zeng D, Dejbakhsh-Jones S, Strober S: Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transportation. Blood 90:453, 1997
16. Ino K, Singh R, Talmadge J: Monocytes from mobilized stem cells inhibit T cell function. J Leukoc Biol 61:583, 1997
17. Kitabayashi A, Hirokawa M, Hatano Y, Lee M, Kuroki J, Niitsu H, Miura AB: Granulocyte colony stimulating factor downregulates allogeneic immune response by posttranscriptional inhibition of tumor necrosis factor-α production. Blood 86:2220, 1995
18. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 89:1629, 1997
19. Mielcarek M, Graf L, Johnson G, Torok-Storb B: Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 92:215, 1998
20. Storeck J, Gooley T, Siadak M, Besinger WI, Maloney DG, Chauncey TR, Flowers M, Sullivan KM, Witherspoon RP, Rowley SD, Hansen JA, Storb R, Appelbaum FR: Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 90:4705, 1997
21. Majolino I, Saglio G, Scime R, Serra A, Cavallaro AM, Fiandaca T, Vasta S, Pampinella M, Catania P, Indovina A, Marceno R, Santoro A: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 17:555, 1996
22. Morse HC, Shen FW, Hammerling U: Genetic nomenclature for loci controlling mouse lymphocyte antigens. Immunogenetics 25:71, 1987
23. Yan XQ, Hartley C, McElroy P, Chang A, McCrea C, McNiece I: Peripheral blood progenitor cells mobilized by recombinant human granulocyte colony-stimulating factor plus recombinant rat stem cell factor contain long-term engrafting cells capable of cellular proliferation for more than two years as shown by serial transplantation in mice. Blood 85:2303, 1995
24. Bungart B, Loeffler M, Goris H, Dontje B, Diehl V, Nijhof W: Differential effects of recombinant human colony stimulating factor (rh G-CSF) on stem cells in marrow, spleen and peripheral blood in mice. Br J Haematol 76:174, 1990
25. Pojda Z, Molineux G, Dexter TM: Hemopoietic effects of short-term in vivo treatment of mice with various doses of rhG-CSF. Exp Hematol 18:27, 1990
26. Nestel F, Kichian K, You-Ten K, Desbarats J, Price K, Lapp WS: The role of endotoxin in the pathogenesis of acute graft-versus-host disease, in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft-vs-Host Disease (ed 2). New York, NY, Marcel Dekker, 1997, p 501
27. Hill GR, Crawford JM, Cooke KJ, Brinson YS, Pan L, Ferrara JLM: Total body irradiation effects on acute graft versus host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood 90:3204, 1997
28. Holler E, Kolb HJ, Moller A, Kempeni J, Lisenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermuller J, Wilmanns W: Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75:1011, 1990
29. Carter LL, Dutton RW: Relative perform-and fas-mediated lysis in T1 and T2 CDS effector populations. J Immunol 155:1028, 1995
30. Graubert TA, Russell JH, Ley T: The role of granzyme B in mutine models of acute graft-versus-host disease and graft rejection. Blood 87:1232, 1996
31. Fowler DH, Kurasawa K, Husebekk A, Cohen PA, Gress RE: Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J Immunol 152:1004, 1994
32. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE: Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540, 1994
33. Krenger W, Snyder KM, Byon CH, Falzarano G, Ferrara JLM: Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155: 585, 1995
34. Kichian K, Nestel FP, Kim D, Ponka P, Lapp WS: IL-12 p40 messenger RNA expression in target organs during acute graft-versus-host disease. J Immunol 157:2851, 1996
35. Via CS, Rus V, Gately MK, Finkelman FD: IL-12 stimulates the development of acute graft-versus-host disease in mice that would normally develop chronic, autoimmune graft-versus-host disease. J Immunol 153:4040, 1994
36. Anasetti C, Hansen JA, Waldmann TA, Applebaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R, Sullivan KM, Witherspoon RP, Binger M, Chizzonite R, Hakimi J, Mould D, Satoh H, Light SE: Treatment of acute graft versus host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor. Blood 84:1320, 1994
37. Ferrara JLM, Marion A, McIntyre JF, Murphy GF, Burakoff SJ: Amelioration of acute graft-versus-host disease due to minor histocompatibility antigens by in vivo administration of anti-interleukin 2 receptor antibody. J Immunol 137:1874, 1986
38. Allen RD, Staley TA, Sidman CL: Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 23:333, 1993
39. Kelso A: Frequency analysis of lymphokine-secreting CD4+ and CD8+ T cells activated in a graft-versus-host reaction. J Immunol 145:2167, 1990
40. Rus V, Svetic A, Nguyen P, Gause WC, Via CS: Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J Immunol 155:2396, 1995
41. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Narula SK, Smith SR, Roncarolo MG, Vallera DA: Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation 66:1220, 1998
42. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S: The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant 19:571, 1997
43. Teshima T, Harada M: Mobilization of peripheral blood progenitor cells for allogeneic transplantation. Cytokines Cell Mol Ther 3:101, 1997
44. Nawa Y, Teshima T, Sunami K, Hiramatsu Y, Yano T, Shinagawa K, Omoto E, Harada M: Responses of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells to alloantigen stimulation. Blood 90:1716, 1997
45. Shenoy S, Brown R, Adkins D, Dipersio J, Mohanakumar T: Constitutive peripheral blood cytokine mRNA expression in growth factor-mobilized normal donors and allogeneic peripheral blood stem cell transplant recipients. Blood 90:562a, 1997 (abstr, suppl 1)
46. Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405, 1992
47. Fowler DH, Gress RE: Graft-versus-host disease as a Th1-type process: Regulation by donor cells of Th2 cytokine phenotype, in Ferrara JLM, Deeg HJ, Burakoff SJ (eds): Graft-vs.-Host Disease. New York, NY, Marcel Dekker, 1997, p 479
48. Remberger M, Ringden O, Markling L: TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 15:99, 1995
49. Holler E, Kolb HJ, Mittermueller J, Kaul M, Ledderose G, Duell T, Seeber B, Schleuning M, Hintermeier-Knabe R, Ertl B, Kempeni J, Wilmanns W: Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 86:890, 1995
50. Hattori K, Hirano T, Tateno M, Oshimi K, Kayagaki N, Yagita H, Okumura K: The synergistic effects of anti-Fas ligand and TNF-α antibody on the prevention of lethal acute graft-versus-host disease in mice. Blood 90:206a, 1997 (abstr, suppl 1)
51. Piguet PF, Grau GE, Allet B, Vassalli PJ: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 166:1280, 1987
52. Pape KA, Khoruts A, Mondino A, Jenkins MK: Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 159:591, 1997
53. Mielcarek M, Roecklein BA, Torok-Storb B: CD14+ cells in granulocyte colony-stimulating factor (GCSF) mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and GCSF by marrow stroma. Blood 87:574, 1996
54. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JL, Antin JH: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 18:975, 1996
55. Collins RH, Shpilberg WR, Drobyski WR, Porter DL, Giralt S: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433, 1997
56. Dazzi F, Goldman JM: Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med 49:329, 1998
57. Helg C, Starobinski M, Jeannet M, Chapuis B: Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 29:301, 1998
58. Russell LA, Jacobsen N, Heilmann C, Simonsen AC, Christensen LD, Vindelov LL: Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients. Bone Marrow Transplant 18:411, 1996
59. Glass B, Uharek L, Zeis M, Dreger P, Löffler H, Steinmann J, Schmitz N: Allogeneic peripheral blood progenitor cell transplantation in a murine model: Evidence for an improved graft-versus-leukemia effect. Blood 90:1694, 1997
60. Glass B, Majolino I, Dreger P, Scime R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N: Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation. Bone Marrow Transplant 20:533, 1997
61. Siegen W, Beyer J, Kingreen D, Blasczyk R, Baurmann H, Schwella N, Schleicher J, Kirsch A, Huhn D: Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Bone Marrow Transplant 22:579, 1998
62. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature 370:650, 1994
63. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528, 1994
64. Levy RB, Baker M, Podack ER: Perform deficiency delays the onset of GVHD following bone marrow transplantation across major and minor histocompatibility barriers. Ann NY Acad Sci 770:366, 1995
65. Baker MB, Riley RL, Podack ER, Levy RB: GVHD-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perform function. Proc Natl Acad Sci USA 94:1366, 1997
66. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB: A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157:5387, 1996
67. Graubert TA, DiPersio JF, Russell JH, Ley TJ: Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100:904, 1997
68. Baker MB, Altman NH, Podack ER, Levy RB: The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med 183:2645, 1996
69. Lin T, Brunner T, Tietz B, Madsen J, Bonfoco E, Reaves M, Huflejt M, Green DR: Fas ligand-mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. J Clin Invest 101:570, 1998
70. Yagita H, Hanabuchi S, Asano Y, Tamura T, Nariuchi H, Okumura K: Fas-mediated cytotoxicity - A new immunoregulatory and pathogenic function of Th1 CD4+ T cells. Immunol Rev 146:223, 1995
71. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ: How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 10:581, 1998
72. Shustov A, Nguyen P, Finkelman F, Elkon KB, Via CS: Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: Up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. J Immunol 161:2848, 1998
73. Matsue H, Kobayashi H, Hosokawa T, Akitaya T, Ohkawara A: Keratinocytes constitutively express the Fas antigen that mediates apoptosis in IFN-γ-treated cultured keratinocytes. Arch Dermatol Res 287:315, 1995